Veracyte, Inc.

VCYT Healthcare Diagnostics & Research

Veracyte, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $517.1 million, up 16.0% from fiscal 2024. In the quarter to June 2026, revenue grew 15.5%, EPS grew 3,300.0% and free cash flow grew 33.0%, each against the same quarter a year earlier. Revenue growth for five consecutive years, operating cash flow growth for three.

43.12 1.27 −2.86%
Market cap
$3.6B
P/E
29.9×
Fwd P/E
45.1×
Dividend yield
—
F-score
8/9
Altman Z
21.08
Beneish M
−2.66
Dividend safety
n/a
Jun '26 Mar '26 Dec '25 Sep '25 Older periods
Piotroski F-Score
8 8 8 8

+8 more TTM periods

ROE
8.77% 6.93% 5.34% 2.49%
ROA
8.09% 6.40% 4.90% 2.29%
ROIC
7.32% 5.35% 4.03% 1.74%
Return on Tangible Assets
21.44% 18.01% 14.72% 7.66%
Average Days of Receivables
35.19 33.76 31.52 35.26
Free Cash Flow per Share
2.08 1.95 1.61 1.25
Free Cash Flow
165.99 155.34 126.63 98.21
Other line items

Show all line items

Columns are period end dates